Dr. Wang is a seasoned leader with a broad and deep understanding of discovery biology and pre-clinical pharmacology spanning early discovery through IND filing in multiple disease areas including cancer biology, immune-oncology, and rare diseases.
Prior to joining FogPharma, Dr. Wang was Director of Biology at Agios Pharmaceuticals, where she had increasing responsibilities overseeing the exploratory pipeline and acting as a program leader for metabolic targets in immune-oncology. Before that, she was the biology and pharmacology lead for enasidenib and ivosidenib, both small molecules that were granted full approval by the FDA for treatment of IDH-mutant R/R AML. She also championed a rare genetic disease program for type II D2HG aciduria at Agios, and demonstrated that enasidenib has therapeutic potential in this disease. She was the co-author of multiple high impact articles in journals including Science, Blood, JCI, Cancer Discovery and Journal of Inherited Metabolic Disease.
Prior to Agios, Dr. Wang led the development of the anti-mutant EGFRT790M antibody at Aveo Pharmaceuticals and was instrumental in the development of the anti-ERBB3 antibody that was partnered with Biogen Idec.
Dr. Wang earned a Ph.D. in Molecular Virology from the Institute of Microbiology from the Chinese Academy of Sciences. Dr. Wang completed two research fellowships, one with the Division of Surgical Oncology at Massachusetts General Hospital at Harvard Medical School and the other with the Department of Laboratory Medicine and Pathology at the Mayo Clinic.